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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with bronchial epithelial changes,
including squamous cell metaplasia and goblet cell hyperplasia. These features are partially attributed to activation
of the epidermal growth factor receptor (EGFR). Whereas smoking cessation reduces respiratory symptoms and
lung function decline in COPD, inflammation persists. We determined epithelial proliferation and composition in
bronchial biopsies from current and ex-smokers with COPD, and its relation to duration of smoking cessation.
Methods: 114 COPD patients were studied cross-sectionally: 99 males/15 females, age 62 ± 8 years, median 42
pack-years, no corticosteroids, current (n = 72) or ex-smokers (n = 42, median cessation duration 3.5 years),
postbronchodilator FEV1 63 ± 9% predicted. Squamous cell metaplasia (%), goblet cell (PAS/Alcian Blue+) area (%),
proliferating (Ki-67+) cell numbers (/mm basement membrane), and EGFR expression (%) were measured in intact
epithelium of bronchial biopsies.
Results: Ex-smokers with COPD had significantly less epithelial squamous cell metaplasia, proliferating cell
numbers, and a trend towards reduced goblet cell area than current smokers with COPD (p = 0.025, p = 0.001,
p = 0.081, respectively), but no significant difference in EGFR expression. Epithelial features were not different
between short-term quitters (<3.5 years) and current smokers. Long-term quitters (≥3.5 years) had less goblet
cell area than both current smokers and short-term quitters (medians: 7.9% vs. 14.4%, p = 0.005; 7.9% vs. 13.5%,
p = 0.008; respectively), and less proliferating cell numbers than current smokers (2.8% vs. 18.6%, p < 0.001).
Conclusion: Ex-smokers with COPD had less bronchial epithelial remodelling than current smokers, which was
only observed after long-term smoking cessation (>3.5 years).
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Background
Chronic Obstructive Pulmonary Disease (COPD) is
defined by progressive airflow limitation and airway
inflammation [1], caused predominantly by cigarette
smoking. Additionally, the airway epithelium undergoes
alterations, including squamous cell metaplasia, goblet
and basal cell hyperplasia [2]. These findings are impor-
tant for our understanding of the pathogenesis of COPD,
since bronchial epithelial cells orchestrate an adequate
maintenance of lung homeostasis by mucus production,
ciliary beating, secretion of antimicrobial products and
adequate immunological drive in response to noxious
stimuli. Goblet cell hyperplasia is more pronounced in
smokers with COPD compared to those without, suggest-
ing a role in the development of airflow limitation [3]. In
addition, it contributes to mucus hypersecretion, which is
associated with morbidity and mortality in COPD [4,5].
Squamous cell metaplasia impairs mucociliary clearance
and contributes to the increased risk of squamous cell car-
cinoma as observed in COPD [6].
The mechanisms underlying epithelial alterations in
COPD are incompletely understood. The epidermal
growth factor receptor (EGFR) cascade has been shown to
be involved in mucin production and goblet cell hyper-
plasia [7,8], repair of damaged epithelium [7,8], as well as
development of squamous cell carcinoma [9]. A wide vari-
ety of stimuli can induce EGFR activation in vitro and in
animals, including cigarette smoke [7,8]. Additionally,
epithelial EGFR expression is increased in bronchial biop-
sies from smokers with [10,11] and without [11,12]
COPD compared to non-smokers. Previously, we have
observed higher epithelial EGFR expression in ex-smokers
with COPD compared to non-COPD, but not in current
smokers, suggesting that current smoking may obscure
differences in EGFR expression [13]. Therefore, EGFR acti-
vation may play a role in epithelial phenotypic alterations
observed in COPD through active smoking.
Smoking cessation improves respiratory symptoms and
lung function decline in COPD, mostly within the first
year after cessation [14,15], but interestingly bronchial
airway inflammation persists or even worsens [16,17]. To
our knowledge, there are no studies comparing bronchial
epithelial features between current and ex-smokers with
established COPD. Possibly, smoking cessation contrib-
utes to restoration of epithelial characteristics in the large
airways of COPD patients, which are directly and contin-
uously exposed to the noxious substances present in ciga-
rette smoke, thereby contributing to the clinical benefits
observed after smoking cessation. Therefore, it needs to be
addressed whether bronchial epithelial alterations and
EGFR expression in large airways are reversible with
smoking cessation and related to the duration of smoking
cessation in COPD.
We hypothesised that bronchial epithelial cell prolifera-
tion and differentiation in patients with COPD is more
pronounced in active smokers than in those who stopped
smoking, and that this difference is influenced by the
duration of smoking cessation. Additionally, we ques-
tioned whether the epithelial changes are associated with
EGFR expression. We therefore investigated the extent of
epithelial goblet cell hyperplasia, proliferation, squamous
cell metaplasia, and EGFR expression in bronchial biop-
sies of current and ex-smokers with established COPD in
a large cross-sectional study.
Methods
Subjects
114 patients with COPD, who participated in a two-centre
trial (Groningen Leiden Universities and Corticosteroids
in Obstructive Lung Disease; GLUCOLD study), were
included in this cross-sectional study. Patient characteris-
tics and methods have been described in detail previously
[17,18]. In brief, all patients had irreversible airflow limi-
tation [postbronchodilator FEV1 and FEV1/IVC < 90% con-
fidence interval (CI) of predicted value] and chronic
respiratory symptoms, they were all current or ex-smokers
(quit = 1 year), with at least 10 pack-years of smoking.
Patients did not use a course of steroids during the last
three months, and did not have maintenance treatment
with inhaled or oral steroids during the last six months.
They were allowed to use short-acting bronchodilators,
and were in clinical stable condition. The medical ethics
committees of each centre approved the study and all
patients gave their written informed consent.
Lung function
Spirometry, reversibility to salbutamol, and diffusing
capacity were measured according to previously described
methods in order to characterise the patients [18].
Bronchoscopy
Fiberoptic bronchoscopy was performed using a standard-
ised protocol according to recent recommendations [19]
as described previously [17]. Smokers were requested to
refrain from smoking on the day of the bronchoscopy.
Patients received premedication (400 μg salbutamol p.i.,
20 mg codeine p.o., 0.5 mg atropine s.c.) and local anaes-
thesia (lidocaine). The bronchoscopies were performed
by experienced pulmonary physicians using a fiberoptic
bronchoscope (18×, outer diameter 6 mm, Pentax Optical
Co., Japan) and pairs of cup forceps (Reda, Tuttlingen,
Germany). Six macroscopically adequate bronchial
biopsy specimens were taken from (sub) segmental cari-
nae in the right or left lower lobe.
Biopsy processing and staining
Four paraffin-embedded biopsies were cut in 4 μm thick
sections and haematoxylin/eosin staining was used for
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evaluation and selection of the two morphological best
biopsies per patient for analysis (without crushing arte-
facts, large blood clots, or only epithelial scrapings). Sec-
tions were stained with Periodic acid-Schiff/Alcian blue
(PAS/AB) and counterstained with Nuclear Fast Red to
identify all secretory cells. Immunohistochemistry was
performed as described previously for inflammatory cells
[17], using specific antibodies against Ki-67 as a marker of
proliferation (Dako M7240, dilution 1:100), and EGFR
(Biogenex nr MU207-UC, dilution 1:50). Antigen
retrieval was obtained using citrate for Ki-67 and pepsin
for EGFR.
Analysis of bronchial biopsies
Total biopsy images were prepared with a 3-chip colour
camera and analysed by means of image analysis soft-
ware (Zeiss Vision KS400 system, Carl Zeiss, Göttingen,
Germany) as follows. First, the length of the basement
membrane was traced of all intact non-squamous meta-
plastic epithelium (A), intact squamous metaplastic epi-
thelium (B), and damaged epithelium (C) in PAS/AB
stained sections, in order to calculate the % intact epithe-
lium [(A+B)/(A+B+C)] and the % metaplastic epithelium
[B/(A+B)]. In addition, the presence of metaplastic epi-
thelium was also scored as absent (0) or present (1).
Intact epithelium (A+B) was defined as a layer of both
basal and columnar cells without detachment from the
basement membrane, including areas of goblet cell
hyperplasia or squamous metaplasia [20]. Consequently,
damaged epithelium (C) was defined as all remaining
epithelium, including denuded basement membrane.
Squamous cell metaplasia was defined as pseudostratis-
fied multilayered epithelium consisting of polygonal
cells covered by flattened layer of squamous cells and
absence of ciliated cells [21]. Subsequently, the number
of Ki-67 positively staining cells was counted in intact
epithelium by a validated full automated procedure [22],
and expressed as the number of Ki-67+ cells/mm base-
ment membrane. Densitometric analysis of PAS/AB and
EGFR in intact epithelium (A+B) was also performed
fully automated as follows [22]. A linear combination of
Red-, and Blue-filtered greyscale images was used, in
order to derive a greyscale image (range 0–255) in which
the "purple" staining (PAS/AB) and the "brown-red"
staining (EGFR) highlighted above background. Results
were expressed as the percentage of intact epithelium
stained by PAS/AB and EGFR. In addition, EGFR staining
intensity of positive areas was expressed as the average
greyvalue, after normalization of the distribution
towards the background peak (white: greyvalue 255) and
subsequent inversion of the greyvalue distribution. Mean
values of two biopsies analysed per patient were used for
analysis.
Statistical analysis
Mean values and standard deviations (SD) were computed
and presented, or median with interquartile range (IQR)
in case of non-normal distributed variables. Since most
epithelial markers were still non-normal distributed after
log-transformation, these data were analysed using non-
parametric tests. Differences between smokers and ex-
smokers were explored using Chi-square tests or 2-tailed
unpaired t-tests for patient characteristics, and Mann
Whitney tests for epithelial features. To study the associa-
tion with duration of smoking cessation, we compared
smokers with ex-smokers who quit <3.5 years and those
who quit ≥3.5 years ago, since this was the median dura-
tion of smoking cessation, using Kruskal-Wallis tests. If
these were significant, Mann Whitney tests were applied
for further exploration of between-group differences. Uni-
variate correlations were evaluated using Spearman rank
correlation coefficient. To analyse correlations with years
since smoking cessation, current smokers were included in
the analysis as 0 years stopped. Multivariate linear regres-
sion analysis was applied to adjust for significant differ-
ences in patient characteristics between the groups, such as
age, pack-years, and FEV1/IVC. PAS/AB+ area was meas-
ured in total intact epithelium, including squamous cell
metaplasia, which by definition does not contain goblet
cells. Therefore, linear regression analysis was also applied
to adjust for % squamous cell metaplasia when analysing
PAS/AB+ differences between groups. SPSS 12.0 (SPSS Inc.,
Chicago, IL) software was used for statistical analysis.
Results
Patient characteristics
Patient characteristics of the 114 patients and subgroups
of smokers and ex-smokers have been described in detail
previously [17,18] (Table 1). Patients had moderate to
severe COPD, based on a postbronchodilator FEV1 of 63.0
(8.8)% predicted, and a median smoking history of 42
pack-years. Of the 114 COPD patients included in this
study, 72 were current smokers and 42 were ex-smokers.
Median duration of smoking cessation in ex-smokers was
3.5 years (IQR: 1–10 years). Differences in patient charac-
teristics between the groups are presented in table 1.
Epithelial features in smokers versus ex-smokers with 
COPD
All 114 patients underwent bronchoscopy; from one
patient (ex-smoker) none of the biopsies taken were ade-
quate for analysis. The median analysed basement mem-
brane length per biopsy was 5.03 (IQR: 3.64–6.14) mm,
of which 1.12 (0.59–2.11) mm was intact epithelium.
Characteristics of intact epithelium in the total group of
patients were: 9.74 (3.54–34.0) Ki-67+ cells/mm BSM, 0
(0–19.7)% squamous cell metaplasia (37.3% of patients
showed squamous cell metaplasia), 12.4 (4.69–18.9)%
PAS/AB+ area, and 10.4 (3.25–18.9)% EGFR+ area.
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Ex-smokers had significantly less Ki-67+ cell numbers, and
% of patients with squamous cell metaplasia as well as %
of epithelium with squamous cell metaplasia (p = 0.001,
p = 0.016, p = 0.025; respectively, Table 2) than current
smokers. PAS/AB+ area also tended to be lower in ex-
smokers, but this was not statistically significant (p =
0.081, Table 2). When adjusting for the presence of squa-
mous metaplasia (which by definition does not contain
goblet cells), the difference in PAS/AB+ area became signif-
icant (p = 0.014). When differences in sex, age, and FEV1/
IVC were taken into account in multivariate linear and
logistic regression analyses, all epithelial differences
remained significant, except for PAS/AB+ area. Epithelial
EGFR+ areas and intensities of positive areas showed no
differences between smokers and ex-smokers with COPD
(Table 2).
Duration of smoking cessation and epithelial features in 
COPD
Ki-67+ cell numbers, the presence of squamous cell
metaplasia, and the % PAS/AB+ area, were different
between current smokers, ex-smokers who quit <3.5 years
ago, and ex-smokers who quit ≥3.5 years ago (Kruskal
Wallis: p = 0.011, p < 0.001, p = 0.049; respectively,
Table 2, Figure 1). Percentage squamous cell metaplasia
and EGFR+ areas and intensities were not significantly
Table 1: Patient characteristics
COPD Ex-smokers
COPD Current smokers combined group quit < 3.5 yrs quit ≥ 3.5 yrs
General
Sex (M/F, n) 59/13 40/2 * 20/1 20/1
Age (yrs) 60 ± 8 64 ± 7 * 61 ± 8 67 ± 4 *†
Pack-years (yrs) 43 (32 – 56) 37 (28 – 53) 45 (29 – 65) 35 (26 – 41) *
Duration of smoking 
cessation (yrs)
- 3.5 (1 – 10) 1.0 (1.0 – 2.0) 10 (6.5 – 14.5)
Smoking duration (yrs) 44 ± 8 41 ± 10 43 ± 11 39 ± 8
Chronic bronchitis (%) 55.6 31.0 * 23.8 * 38.1
Lung Function
Postbronchodilator FEV1 
(%pred)
63.3 ± 8.3 62.5 ± 9.6 62.6 ± 10 62.5 ± 9.4
Postbronchodilator FEV1/
IVC (%)
49.5 ± 8.5 46.0 ± 8.3 * 45.3 ± 8.6 * 46.7 ± 8.1
ΔFEV1 (%pred) 6.9 ± 5.2 6.8 ± 4.5 6.9 ± 3.9 6.8 ± 5.1
KCO (%pred) 73.3 ± 25.1 80.4 ± 25.9 75.3 ± 24.9 85.7 ± 26.5 *
Data are presented as mean ± standard deviation or median (IQR: 25th – 75th percentile), ex-smokers are divided in two groups based on median 
duration of smoking cessation (3.5 years). FEV1 = Forced expiratory volume in one second, IVC = Inspiratory vital capacity, ΔFEV1 = Reversibility to 
salbutamol (change in FEV1 as percentage of predicted), KCO = Diffusing capacity for carbon monoxide per liter alveolar volume, pred = predicted. 
Patient characteristics have been described before [17].
* p < 0.05: compared to COPD smokers [Chi-square tests for sex differences, 2-tailed unpaired t-tests for other (log-transformed) data]; 
† p < 0.05: compared to COPD ex-smokers who quit <3.5 yrs (2-tailed unpaired t-tests)
Table 2: Bronchial epithelial features of smokers and ex-smokers with COPD
                                          COPD Ex-smokers
COPD Smokers combined group quit < 3.5 years quit ≥3.5 years p-value 
SCM (% of epithelium) 0 (0–27.5) 0 (0-0)* 0 (0–10.4) 0 (0-0) 0.076
SCM (% of patients) 45.7 22.5* 26.3 19.0* 0.049
PAS/AB+ area (%) 14.4 (5.2–20.7) 8.1 (3.7–17.2)† 13.5 (6.6–19.6) 7.9 (2.2–16.2)*‡ 0.011
Ki-67+ cells (/mm 
BSM)
18.6 (5.3–38.8) 6.2 (1.5–15.6)* 6.9 (4.4–27.6) 2.8 (0.23–13.1)* <0.001
EGFR+ area (%) 11.4 (3.2–17.6) 8.2 (3.2–20.4) 6.7 (2.4–20.4) 8.6 (3.9–21.5) 0.95
Intensity EGFR+ area 
(grey value)
697 (175–1182) 513 (203–1479) 372 (125–1479) 517 (215–1424) 0.95
Data represent median (IQR: 25th – 75th percentile). PAS/AB = Periodic acid-Schiff/Alcian blue, SCM = squamous cell metaplasia, EGFR = Epidermal 
growth factor receptor.
* p < 0.05: compared to COPD smokers, † p < 0.05: compared to COPD smokers adjusted for differences in squamous cell metaplasia (linear 
regression), ‡ p < 0.05: compared to COPD ex-smokers who quit <3.5 yrs, §p-value from Kruskal-Wallis test between current smokers, < and ≥3.5 
yrs ex-smokers with COPD.
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different between these three groups (Table 2, Figure 1).
There were no differences between current smokers and
those who quit <3.5 years ago for any of the epithelial fea-
tures. In contrast, those who quit ≥3.5 years ago had sig-
nificantly less Ki-67+ cell numbers, presence of squamous
cell metaplasia, and % PAS/AB+ area than current smokers
(p < 0.001, p = 0.029, p = 0.005, respectively; Table 2,
Figure 1). The differences in PAS/AB and Ki-67 remained
significant when adjusting for age and pack-year differ-
ences between both groups. Moreover, the % PAS/AB+
area was also lower in long-term quitters than those who
quit <3.5 years ago (p = 0.008), and tended to be lower for
Ki-67+ cell numbers (p = 0.050). When adjusting for dif-
ferences in age, PAS/AB significance was lost (p = 0.061).
There was a significant inverse relationship between the
duration of smoking cessation (including current smokers
as 0 years stopped) and Ki-67+ cell numbers (rs = -0.354,
p < 0.001), % squamous cell metaplasia (rs = -0.212,
p = 0.004), and % PAS/AB+ area (rs = -0.235; p = 0.013),
but not with EGFR expression.
Relation of epithelial features with smoking, symptoms 
and lung function
The duration of smoking tended to be associated with the
number of Ki-67+ cells (rs = 0.180, p = 0.065), whereas the
number of pack-years smoked was not associated with
epithelial features. 46.5% of all patients reported
symptoms of chronic bronchitis, and although ex-smok-
ers had significantly less symptoms of chronic bronchitis
(Table 1) and % of PAS/AB+ area, there was no relation
between the presence of these symptoms and the % of
PAS/AB+ area (p = 0.78). Epithelial features were not asso-
ciated with the degree of airflow limitation.
Epithelial phenotype in smokers (S) and ex-smokers with COPDFigure 1
Epithelial phenotype in smokers (S) and ex-smokers with COPD. Individual values of: (A) % PAS/AB+ area of intact 
epithelium, (B) Ki-67+ cells (/mm basement membrane = BSM) in intact epithelium, (C) % squamous cell metaplasia (SCM) of 
intact epithelium (note: in a large % of patients no SCM was observed), (D) % EGFR+ area of intact epithelium. Data are 
grouped by COPD smokers (S), COPD ex-smokers who quit < 3.5 years ago (<3.5 yr), and who quit ≥3.5 years ago (≥3.5 yr). 
Horizontal bars represent median values, * p < 0.05.
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Relation between epithelial cell proliferation and 
differentiation
Ki-67+ cell numbers and the % squamous cell metaplasia
were positively associated with one another (rs = 0.586,
p < 0.001). Finally, Ki-67+ cell numbers were also posi-
tively associated with % EGFR+ area (rs = 0.210, p = 0.031).
Discussion
In the present study, we demonstrated that long-term ex-
smokers with COPD had less bronchial epithelial mucin
stores, proliferating cells, and squamous cell metaplasia
than current smokers with COPD. Moreover, these epithe-
lial differences in ex-smokers were only significant after a
long-term period of smoking cessation (>3.5 years). In
contrast, epithelial EGFR expression was not different
between current and ex-smokers with COPD. These
results may indicate that smoking cessation reverses
smoking-induced bronchial epithelial cell proliferation
and differentiation in patients with COPD, and the mag-
nitude of this effect increases with longer duration of
smoking cessation. In addition, our results suggest that
these smoking cessation-induced epithelial changes in
COPD are not accompanied by reduced EGFR expression.
Our observation of lower bronchial epithelial mucin
stores, proliferating cells, and squamous cell metaplasia in
large airways of ex-smokers as compared to current smok-
ers with COPD, and the association with duration of ces-
sation, is novel. These results are in contrast to other,
smaller studies showing no differences in epithelial fea-
tures in ex-smokers compared to smokers both with and
without COPD [21,23]. However, the finding that ex-
smokers with chronic bronchitis (with or without airflow
limitation), had less goblet cell metaplasia in small air-
ways than current smokers [24] is in line with our findings
in COPD patients. The effect of smoking cessation and
duration of cessation on squamous cell metaplasia and
proliferation has been examined previously in bronchial
biopsies [25]. Although it was not mentioned whether
these patients had respiratory symptoms and/or COPD,
the latter study also reported less squamous cell metapla-
sia and epithelial proliferation in ex-smokers. Our result
of similar EGFR expression in ex-smokers compared to
current smokers with COPD, is also novel and in contrast
with observations in smokers without COPD, where
lower bronchial EGFR expression was observed in ex-
smokers [12]. Taken together, it can now be inferred that
smoking cessation results in decreased epithelial mucin
stores, proliferation, and squamous cell metaplasia, in
large airways of patients with COPD, but that it does not
affect EGFR expression.
There are a few important considerations when interpret-
ing our results. We included a large (n = 114) group of
well-characterised patients with stable COPD, not inhal-
ing steroids for at least six months or oral steroids for at
least three months, and without a clinical diagnosis of
asthma. First, it needs to be emphasised that this was a
cross-sectional study, and it cannot be ruled out that our
ex-smoking group is a selected group of patients who quit
smoking because they suffered more from smoking
related symptoms, and may already have had a different
epithelial morphology before quitting. Yet, in the present
study ex-smokers had significantly less respiratory symp-
toms than current smokers, whilst having similar pack-
years and duration of smoking. In addition, we also
reported analyses adjusted for clinical differences between
the groups (sex, age, FEV1/IVC, pack-years). Second, com-
parable to previously published cross-sectional studies we
did not confirm smoking status by laboratory tests, and
therefore cannot rule out that some ex-smokers were still
smoking. Third, our definitions of intact epithelium and
squamous cell metaplasia were very strict, which could
have led to an underestimation. Fourth, we cannot
exclude the possibility that mechanical injury induced
during bronchoscopy may have interfered with our analy-
ses of epithelial damage. Fifth, we applied fully auto-
mated image analysis for quantification of cell numbers,
positively stained areas, and densitometry analyses, and
therefore minimised potential observer biases. Finally, we
did not include a control group of smokers without
COPD and therefore cannot conclude whether the
observed effects of smoking cessation are specific to
COPD. Taken together, it seems unlikely that our results
are strongly affected by methodological errors.
How can we interpret these data? The (partial) reversibil-
ity of mucin stores, squamous cell metaplasia, and prolif-
eration after smoking cessation, supports a causal
relationship between cigarette smoke exposure and these
epithelial features in COPD. In vivo, the proliferative
response in smokers may be due to a direct mitogenic
effect of cigarette smoke (26), but may also result from
chronic inflammation, tissue damage and wound healing
[26]. An inadequate repair response to smoke-induced
injury may lead to a sustained increase in epithelial prolif-
eration and/or altered differentiation. Increased prolifera-
tion may accompany squamous cell metaplasia [21,25],
which is in line with our observation that squamous cell
metaplasia is related to proliferating cell numbers. This
squamous metaplasia may serve to protect the underlying
tissue against the injurious effects of cigarette smoke.
According to our results, smoking cessation may reverse
this process in COPD, at least partially.
The observed decrease in mucin stores in long-term ex-
smokers with COPD, and its relation with duration of
smoking cessation, can be explained by decreased goblet
cell numbers, decreased mucin production, and/or
increased mucin secretion. The few previous studies
Respiratory Research 2007, 8:85 http://respiratory-research.com/content/8/1/85
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examining goblet cell hyperplasia in relation to smoking
cessation in humans used semi-quantitative scoring sys-
tems, but not cell numbers [23,24]. Animal studies sug-
gest that a reduction in secretory cell numbers occurs after
smoking cessation [27]. The observed decrease in mucin
stores in ex-smokers in our study probably reflects a
decrease in the major mucin in surface epithelium,
MUC5AC [28]. MUC5AC and total mucin in bronchial
epithelium are correlated, and both are increased in
smokers compared to non-smokers [11]. In addition,
small airway epithelial MUC5AC expression is lower in
ex-smokers compared to current smokers with and with-
out COPD [29], which is also in line with our conclusion.
Although ex-smokers exhibited fewer symptoms of
chronic bronchitis and a smaller amount of mucin stores,
chronic bronchitis was not associated with mucin stores.
This can be explained by the fact that mucin is produced
by both goblet cells in the surface epithelium and by sub-
mucosal glands [30], whereas these latter were not
included in the present analysis. This conclusion is sup-
ported by the results of a recent study that also failed to
reveal differences in epithelial mucin expression in
peripheral airways of COPD patients with or without
chronic bronchitis [29]. Finally, it needs to be noted that
our study focused on mucin expression and not on secre-
tion, whereas the latter is the main feature of chronic
bronchitis.
The changes in epithelial mucin stores, proliferating cells,
and squamous cell metaplasia were most pronounced in
COPD patients who had stopped smoking more than 3.5
years ago. Correspondingly, inflammation initially per-
sists after smoking cessation [17,31]. This suggests a long-
term effect of smoking on bronchial regulatory networks,
which is not restored immediately after removing the ini-
tial stimulus, i.e. cigarette smoke. In contrast, the greatest
improvements in respiratory symptoms and lung function
decline occur within the first year after cessation [14,15].
Therefore, other pathological mechanisms that reverse
more rapidly after cessation should be involved in these
clinical beneficial effects of smoking cessation.
Cigarette smoke causes both mucus hypersecretion and
increases the number of goblet cells through activation of
the EGFR system [32]. In the present study, there were no
differences between current and ex-smokers with COPD
in EGFR expression, suggesting that differences in EGFR
activation, rather than expression, are present in ex-versus
current smokers with COPD. We did not pursue this pos-
sibility further, since recent attempts in our laboratory to
demonstrate in situ EGFR phosphorylation in lung tissue
by immunohistochemical methods using phosphospe-
cific antibodies were not successful [13]. Since pro-
inflammatory cytokines, such as TNF-α, increase EGFR
expression [33], our observation that there is no differ-
ence in EGFR expression between ex-and current smokers
may be related to the persistence of bronchial inflamma-
tion [16,17] in ex-smokers with COPD. The large inter-
individual differences in EGFR expression could also
explain why there were no differences between the groups
in this cross-sectional analysis. Alternatively, EGFR inde-
pendent pathways may contribute to epithelial mucin
production.
What could be the clinical implications of our findings?
There is good evidence that smoking cessation results in
less respiratory symptoms [14], less decline in FEV1 [15],
and less severe airway hyperresponsiveness [34,35],
whereas inflammation persists [16,17]. Our data suggest
that smoking-induced bronchial epithelial goblet cell
hyperplasia, proliferation, and squamous cell metaplasia
are reduced with long-term smoking cessation. These epi-
thelial features might contribute to COPD by facilitating
colonization of the airways by respiratory pathogens, sec-
ondary to loss of cilia, increased mucus secretion, and epi-
thelial injury [36]. The chronic colonization of the
airways may enhance airway inflammation and further
epithelial injury. In addition, mucus hypersecretion may
cause airways obstruction in peripheral airways [37].
Reversal of epithelial remodelling may therefore contrib-
ute to reduced progression of COPD attributable to
restored mucociliary clearance, resulting in reduced respi-
ratory colonization [38] and exacerbations, and less small
airways obstruction. In addition, reduced epithelial prolif-
eration and squamous cell metaplasia in ex-smokers with
COPD may decrease the risk of squamous cell carcinoma
development. Whether the observed (partial) reversibility
of epithelial remodelling is associated with the clinical
benefits of smoking cessation in patients with COPD,
remains to be established in longitudinal studies.
Conclusion
The present study has shown that ex-smokers with COPD
have less bronchial epithelial mucin stores, proliferating
cells, and squamous cell metaplasia than current smokers
with COPD, whereas epithelial EGFR expression was not
different between both groups. These epithelial changes in
ex-smokers were more pronounced with longer duration
of smoking cessation, and significant after 3.5 years smok-
ing cessation. This suggests that the clinical benefits of
smoking cessation in COPD patients may be in part attrib-
utable to a restoration of epithelial homeostasis.
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